Please login to the form below

Not currently logged in
Email:
Password:

Bayer raises sales predictions for new pharma products

Expects Xarelto, Eylea, Stivarga, Xofigo and Adepas to make €7.5bn at peak
Bayer symbol

Bayer has added almost €2bn to its peak sales predictions for a clutch of five recently-launched products amid buoyant pharma division growth in the last quarter of 2013.

The new products - anticoagulant Xarelto (rivaroxaban), eye medicine Eylea (aflibercept), cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) and pulmonary hypertension therapy Adempas (riociguat) - are now expected to add around €7.5bn a year to Bayer's turnover at peak, according to chief executive Marijn Dekkers.

Over the course of 2013 as a whole the five posted sales of €1.52bn - four times the level of 2012 - helping Bayer's pharma unit to grow more than 9 per cent to €11.19bn out of total group sales up by one point to €40.16bn.

Most of the predicted sales increase has been attributed to Xarelto, and expected peak sales have increased from €2bn to €3.5bn a year, said Dekkers. In the fourth quarter Xarelto became Bayer's top-selling drug with sales of €316m, up from €131m a year ago.

The picture was not entirely positive in the fourth quarter, with Bayer's former biggest-selling pharma product Betaseron (interferon beta-1b) for multiple sclerosis falling more than 21 per cent to €259m on higher levels of competition from new, orally active drugs, while the Yaz/Yasmin birth control franchise fell 19 per cent to €219m.

Haemophilia therapy Kogenate (antihemophilic factor) added €294m to the tally, down 8 per cent, which the company attributed to shifts in ordering patterns.

Fresh from announcing a deal to buy Chinese over-the-counter drugmaker Dihon Pharmaceutical, Bayer also reported a 4 per cent sales decline for its consumer health division to €1.96bn - in line with expectations. Growth in Europe was offset by declines in North America, Asia-Pacific and other areas of the world.

For 2014 Bayer is predicting another high single-digit growth rate for its pharma business, with overall group sales expected to rise 5 per cent to €41bn-€42bn. Consumer health should return to low- to mid-single-digit growth in the wake of the Dihon deal, it added.

Article by
Phil Taylor

28th February 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics